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ABSTRACT
Objectives: To determine the frequency of occult uterine leiomyosarcomas following hysterectomies and myomectomies 
performed for benign reasons at our clinic and to draw comparisons with similar studies in the literature.
Material and methods: All hysterectomies and myomectomies that have been performed for benign reasons at our clinic 
between 2010 and 2017 were retrospectively examined via the hospital’s information system and the patients that were 
found to have leiomyosarcomas were analysed. The incidence of occult uterine leiomyosarcoma per 1000 surgeries at our 
clinic was calculated using the Wilson score interval.
Results: A total of 6,173 hysterectomies were performed, and occult uterine leiomyosarcoma was identified in 5 patients. The 
incidence of occult uterine leiomyosarcoma was calculated to be 0.08% (95% CI 0.03–0.018%). Only 1 of the 771 patients 
who underwent myomectomy was identified with occult uterine leiomyosarcoma, making its incidence in myomectomy 
0.12% (95% CI 0.02–0.073%). When all the patients are considered, occult uterine leiomyosarcoma was identified in 6 of the 
6,944 patients, and the general incidence of occult uterine leiomyosarcoma was calculated as 0.08% (95% CI 0.03–0.018%). 
Conclusions: In our study, the incidence of occult uterine sarcoma following myomectomy and hysterectomy was found 
to be lower than that reported in the literature. The reason for this lower incidence includes not only genetic causes and 
racial differences but also preoperative imaging, endometrial and cervical sampling that is performed on every patient. 
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INTRODUCTION
Hysterectomy is a commonly performed surgery in gynae-
cology, and it is reported that approximately 600,000 hyster-
ectomies are performed annually in the South Korea, which 
is roughly similar to the number of such surgeries performed 
annually in the United States [1, 2]. A study conducted in Tur-
key in 2017 on secondary care hospitals affiliated with the 
Ministry of Health revealed that the total number of hysterec-
tomies performed annually was more than 15,000 [3]. The large 
majority of hysterectomies are performed for benign reasons 
worldwide. According to a society-wide study carried out in the 
United States, the indications for hysterectomy include uterine 
fibroids in 51.4% of the cases, abnormal uterine bleeding in 
41.7%, endometriosis in 30% and uterine prolapse in 18.2% [4]. 
Another study in the United States determined that approxi-
mately 43,000 myomectomies are performed annually due to 
uterine fibroids, which is the most common reason for hysterec-
tomy, whereas this figure is approximately 9,412 for Turkey [3, 5].
Uterine sarcomas reportedly account for 1% of all gynae-
cological cancers, and 3–7% of uterus-related cancers [6]. 
According to their histological classification, 40% of uterine 
sarcomas are carcinosarcomas, 40% are leiomyosarcomas, 
10–15% are endometrial stromal sarcomas and 5–10% are 
undifferentiated sarcomas [7]. Leiomyosarcomas, listed in this 
classification, show clinical findings similar to those of uterine 
fibroids, which leads to certain difficulties in the preoperative 
diagnosis and treatment of patients [7–9]. Although they are 
not specific, leiomyosarcomas are associated with several risk 
factors that are different from those associated with uterine 
fibroids, such as being from the black community, being diag-
nosed above the age of 60 years, use of tamoxifen or exposure 
to pelvic radiation, and retinoblastoma in childhood [10–13].
In recent years, there has been an increase in the number 
of hysterectomies and myomectomies performed world-
wide through minimally invasive methods for indications of 
uterine fibroids, leading to a greater need for the morcella-
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tion of specimens. In this context, the U.S. Food and Drug 
Administration (FDA) 2014 has drawn attention to the pos-
sibility of occult gynaecological cancers, particularly uter-
ine sarcomas that are associated with uterine fibroids [14]. 
Based on the possibility of uncontrolled spread within the 
abdomen in gynaecological cancers that could not be iden-
tified preoperatively, have been conducted following the 
aforementioned FDA report for determining the frequency 
of occult uterine sarcomas. A review of the literature shows 
that the frequency of occult uterine sarcomas tends to vary 
in the range of 0–0.89% [5, 15]. 
Objectives
The present study aimed to determine the frequency of 
occult uterine leiomyosarcomas following hysterectomies 
and myomectomies performed for benign reasons at our 
clinic and to draw comparisons with similar studies in the 
literature.
MATERIAL AND METHODS
All hysterectomies and myomectomies that have been 
performed at Izmir University of Health Sciences Tepecik 
Training and Research Hospital between 2010 and 2017 were 
retrospectively examined via the hospital’s information 
system. The preoperative diagnoses of all patients were 
examined. The study included patients who were oper-
ated for benign reasons, such as pelvic pain, leiomyoma, 
endometriosis, abnormal uterine bleeding and uterovaginal 
prolapse. For the past 10 years, our clinic has been collecting 
cervical smear samples for endometrial sampling purposes 
from all patients who have planned hysterectomy surgeries, 
with sample collection being performed at least 1 month 
before the date of surgery. Therefore, all patients included 
into the study had their preoperative assessment done ac-
cording to these principles.
Patients with planned operations for diagnosed gy-
naecological or non-gynaecological cancers, patients with 
dysplasia or atypical endometrial hyperplasia, patients with 
prior surgeries performed for staging purposes, patients 
with suspicions of malignancy in their medical history and 
patients with hysterectomies performed for obstetric rea-
sons were excluded from the study. The cases of uterine 
sarcomas that were initially not detected during preopera-
tive examination but were subsequently identified as a result 
of postoperative histopathological examinations performed 
following hysterectomy and myomectomy surgeries were 
classified based on the guidelines of the World Health Or-
ganisation [16], and the patients that were found to have 
leiomyosarcomas were analysed.
The information of patients identified with occult uter-
ine leiomyosarcomas was examined in detail through the 
hospital’s information system and patient files. An analysis 
was performed on the patients’ demographic characteristics, 
preoperative findings, primary surgical indication and type, 
weight of specimen, final pathology results, postoperative 
conditions and treatments and patient survival. The inci-
dence of occult uterine leiomyosarcoma per 1000 surgeries 
at our clinic was calculated using the Wilson score interval. 
Simultaneously, our results on occult uterine leiomyosar-
coma were compared with those of suitable studies found 
by performing searches on PubMed using the MeSH terms 
‘Hysterectomy’, ‘Myomectomy’, ‘Adenosarcoma’, ‘Leiomyosar-
coma’ and ‘Carcinosarcoma’.
Statistical analysis
The data were statistically analysed using SPSS 22.0 (SPSS 
Inc., Chicago, Illinois) software. The normality distribution of 
continuous variables was evaluated with a normality test that 
was suitable to the number of data collected. Mean ± stand-
ard deviation or median (min. and max.) were used for de-
scriptive continuous variables. The Mann–Whitney U test 
was used for the comparison of variables lacking normal 
distribution, whereas the Student’s t-test was used for the 
comparison of variables with normal distribution. Categorical 
variables were presented as number of cases and percent-
ages. A value of p < 0.05 was considered to be significant. 
EpiTools epidemiologic calculators (http://epitools.ausvet.
com.au) were used for the Wilson score interval.
RESULTS
A total of 6,173 hysterectomies were performed at 
our clinic over 7 years, and occult uterine leiomyosarcoma 
was identified in 5 patients. The incidence of occult uter-
ine leiomyosarcoma was calculated to be 0.08% (95% CI 
0.03–0.018%). Only 1 of the 771 patients who underwent 
myomectomy was identified with occult uterine leiomyo-
sarcoma, making its incidence in myomectomy 0.12% 
(95% CI 0.02–0.073%). When all the patients are consid-
ered, occult uterine leiomyosarcoma was identified in 6 of 
the 6,944 patients, and the general incidence of occult 
uterine leiomyosarcoma was calculated as 0.08% (95% CI 
0.03–0.018%), which is similar to its incidence in patients un-
dergoing hysterectomy. Among the patients included in the 
study, 4,572 (65.8%) underwent abdominal hysterectomy, 
1,022 (14.7%) underwent total laparoscopic hysterectomy, 
579 (8.3%) underwent vaginal hysterectomy and 771 (11.1%) 
underwent myomectomy.
The most common indication of the patients who un-
derwent abdominal and laparoscopic hysterectomy was 
symptomatic leiomyoma (39%), whereas their second most 
common indication for hysterectomy was treatment-resist-
ant menometrorrhagia (23%). The most common indication 
of patients who underwent vaginal hysterectomy was pelvic 
organ prolapse (64%).
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Among the patients included in our study, the primary 
surgical indication of those identified with occult uterine 
leiomyosarcoma was for symptomatic leiomyoma in all 
of them. Moreover, 2 patients also had an indication for 
treatment-resistant menometrorrhagia in addition to symp-
tomatic leiomyoma.
The mean age of the patients included into the analysis 
was 48.63 years, whereas our subgroup analysis revealed 
that the patients who underwent abdominal hysterectomy, 
total laparoscopic hysterectomy, vaginal hysterectomy and 
myomectomy had a mean age of 48.91, 49.20, 61.20 and 
37.28 years, respectively. The mean age of patients identi-
fied with occult uterine leiomyosarcoma was 46.5 years, 
which was lower than that of other patients. The patients’ 
body mass indices varied between 22 and 28. None of the 
patients identified with occult uterine leiomyosarcoma 
had any tamoxifen use prior to surgery. One patient used 
an oral contraceptive, whereas none of the other patients 
had any oral contraceptive use or received hormone replace-
ment treatment. The uterus weight of the patients who 
underwent hysterectomy varied between 146 and 2500 g. 
The patient whose uterus weighed 2500 g was found to 
be obese compared with the other patients, and it was 
understood that this patient did not attend her routine 
gynaecological examinations regularly.
The findings of the patients are summarised in Table 1. 
Six patients identified with occult uterine leiomyosarcoma 
had no pathological findings in their preoperative cervical 
smear and endometrial samples. Preoperative ultrasonogra-
phy examination was performed on only 5 patients, whereas 
patient number 4 also had a magnetic resonance imaging 
performed in addition to ultrasonography, although their 
findings were not interpreted to be indicative of malignancy. 
All of the patients were operated by gynaecology special-
ists under suitable conditions. Five patients had oophorecto-
mies performed in addition to hysterectomy, and 1 patient 
only had a myomectomy surgery performed. Morcellation 
was not applied in any patient. In all patients, the operated 
piece was removed as a single whole piece, and we observed 
that, except for patient number 4, a frozen sample examina-
tion was not performed on the collected pieces, as there was 
no suspicion of malignancy. A frozen sample examination 
was performed on only 1 patient. The results of this exami-
nation were checked only according to the mitosis count, 
and the final pathological diagnosis of leiomyosarcoma was 
established in the final pathological examination.
Three patients identified with occult uterine leiomyo-
sarcoma had stage 1c leiomyosarcoma, two had stage 1b 
leiomyosarcoma and one had stage 2 leiomyosarcoma. 
Combined radiotherapy plus chemotherapy was used in 
the secondary treatment of 4 patients, whereas 1 patient 
received only radiotherapy and 1 received conservative 
treatment. None of the patients showed recurrence during 
their monitoring period, and all patients were still alive at 
the time this article was penned. The mean disease-free 
survival was determined as 60 (40–86) months.
DISCUSSION
A total of 6,944 patients who underwent hysterecto-
my and myomectomy surgeries at our clinic for benign 
reasons within a seven-year period were included in the 
study. Occult uterine leiomyosarcoma was identified in 
6 of the 6,944 patients, and the general incidence of occult 
uterine leiomyosarcoma was calculated as 0.08% (95% CI 
0.03–0.018%).  Following the FDA’s notable 2014 report, 
which presented a prevalence of 1/498 (0.2%) for occult 
uterine leiomyosarcoma, there has been a visible increase in 
the literature in the frequency of studies conducted on this 
subject [17]. Many studies have reported the rates of occult 
uterine leiomyosarcoma at their own clinics, with incidences 
varying between 0% and 0.89%. A summary of these studies 
is provided in Table 2.
In their 2008 study that focused solely on patients who 
underwent myomectomy, Sinha et al. [18] determined the 
incidence of occult uterine leiomyosarcoma to be 0.40%, 
whereas Brohl et al. [19] identified this incidence to be 
0.24%. In our analysis, the rate of occult uterine leiomyo-
sarcoma following myomectomy surgery was calculated 
Table 1. Information of patients with occult uterine leiomyosarcoma
Patient Age [years] BMI
Primary 
diagnosis Primary surgery
Uterine 
weight [g]
Sarcoma 
type Stage Treatment Status
Follow-up 
[months]
1 52 28 ULM TAH 241 LMS 1c RT + CT Live 60
2 47 29 ULM + TRM TAH 146 LMS 1b RT + CT Live 48
3 54 31 ULM TAH 610 LMS 2 RT + CT Live 40
4 47 38 ULM TAH 2500 LMS 1c RT Live 60
5 47 27 ULM + TRM TAH 469 LMS 1c RT + CT Live 86
6 32 22 ULM Myomectomy 128 LMS 1b None Live 72
ULM — uterine leiomyoma; TRM — treatment-resistent menorrhagia; TAH — total abdominal hysterectomy; LMS — leiomyosarcoma; RT — radiotherapy;  
CT — chemotherapy
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to be 0.12%. In addition to the specific geographical region 
where analyses are performed, racial and genetic differences 
are possibly the causes of these different results.
A review of the literature shows that while the incidence 
of occult uterine leiomyosarcoma in patients who undergo 
only hysterectomies can be 0.89% at the highest [15], the 
incidence of occult uterine leiomyosarcoma varies between 
0.20% and 0.38% when all patients who underwent hys-
terectomy and myomectomy are included in the analysis 
[20, 21]. In our study, the incidence of leiomyosarcoma was 
calculated to be 0.08%, which is relatively lower than that 
reported in other studies. There are only a limited number of 
studies in Turkey regarding the incidence of occult leiomyo-
sarcoma; however, a previous study in Turkey has reported 
an annual leiomyosarcoma incidence of 0.26% [22].
Currently, no tests that might be used to diagnose 
leiomyosarcoma preoperatively during the evaluation of 
patients for uterine leiomyoma are available. Unexplained 
pain and atypical vaginal bleeding in the presence of uterine 
leiomyoma along with a rapid increase in the leiomyoma’s 
size can serve as warnings with regards to leiomyosarcoma 
[7, 23]. As vaginal bleeding independently can be observed 
in submucosal myomas of any additional pathology and 
pain can also occur following a possible degeneration in 
the myomas, these two symptoms — vaginal bleeding and 
pain — have rather low value in preoperative differential 
diagnosis [24, 25]. Parker et al have also reported that a rapid 
increase in the size of the uterus cannot be used in distin-
guishing leiomyosarcomas from leiomyomas [26]. 
As uterine leiomyosarcomas that have not been identi-
fied during preoperative differential diagnosis can possibly 
spread into the abdominal cavity, it is suggested that it is not 
suitable to perform power morcellation following minimally 
invasive procedures in the absence of adequate protective 
equipment for the intra-abdominal area [18, 20]. The major 
limitation of this study was its retrospective nature. The fact 
that the hospital’s information underwent a major overhaul 
in the 2000s and that we could not include patients admit-
ted prior to this period considerably restricted our ability to 
increase our study sample size. Nevertheless, compared with 
the data obtained from single-centre studies performed in 
Turkey and worldwide, we believe that our study makes 
a marked contribution to the literature with its number of 
patients and the rates it determined. Simultaneously, we 
also believe that our study serves as an important source 
because it illustrates the situation in Turkey based on com-
parisons with other studies. 
CONCLUSIONS
In our study, the incidence of occult uterine sarcoma 
following myomectomy and hysterectomy was found to be 
lower than that reported in the literature. We believe that 
the underlying reason for this lower incidence includes not 
only genetic causes and racial differences but also preop-
erative imaging and preoperative endometrial and cervical 
sampling that is performed on every patient. Although it 
might not seem cost-effective when viewed solely form 
a cost-effectiveness standpoint, we believe that detailed 
Table 2. Comparison of occult uterine leiomyosarcoma studies
Author Year Centers that include study Operation type Study duration
Number of 
patients
Rate of Occult
LMS,
n (per 100)
Parker et al. [26] 1994 Two Hysterectomy, Myomectomy 1988–1992 1332 3 (0.23)
DiNapoli et al. [21] 2018 Single Hysterectomy, Myomectomy 2010–2014 1959 4 (0.20)
Kundu et al. [20] 2017 Single Hysterectomy, Myomectomy 2004–2014 2825 10 (0.35)
Seidman et al. [27] 2012 Single Hysterectomy, Myomectomy 2005–2010 1091 2 (0.18)
Brohl et al. [19] 2015 Multiple Myomectomy 2005–2014 2075 5 (0.24)
Sinha et al. [18] 2008 Single Myomectomy 1998–2005 505 2 (0.40)
Multinu et al. [28] 2019 Multi Hysterectomy 1999–2013 3759 4 (0.11)
Leung et al. [29] 2008 Single Hysterectomy 1996–2005 1297 3 (0.23)
Ramm et al. [30] 2012 Multiple Hysterectomy 2004–2009 708 1 (0.14)
Kho et al. [15] 2016 Single Hysterectomy 2000–2014 10109 9 (0.89)
Yuk et al. [2] 2016 Multiple Hysterectomy 2010–2012 12850 8 (0.06)
Theben et al. [31] 2013 Single Hysterectomy 2005–2010 1584 2 (0.13)
Wright et al. [32] 2014 Multiple Hysterectomy 2006–2012 36470 none
Wan et al. [33] 2013 Single Hysterectomy 2003–2011 640 1 (0.16)
Current Study Single Hysterectomy, Myomectomy 2010–2017 6944 6 (0.08)
LMS — leiomyosarcoma
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preoperative examination is useful given the possibility of 
medico-legal complications, additional treatment needs of 
patients and pain and anxiety the patients might experience. 
Conducting international multi-centre prospective studies 
on such patients will likely play a guiding role in determin-
ing the appropriate incidence of leiomyosarcoma and in 
identifying the proper measures against it.
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